Beta-amyloid PET scan for amyloid-related diseases
Part of Brain & nervous system, Mental health clinical trials.
This trial is testing whether a special scan (beta-amyloid PET/CT) can help detect abnormal protein clumps in the brain that are linked to certain diseases, including cancer. The scan might help doctors better understand and track these conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be 18 years old or older
- Have a known or suspected malignant tumor (cancer) that has been confirmed by tests like MRI, CT, or biopsy
- Be scheduled to have a beta-amyloid PET/CT scan
- Be able to give informed consent (or have a parent or legal representative do so)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a special PET/CT scan (Pan-Amyloid) that finds abnormal protein deposits (amyloid) in the heart and body. It is for people who have or may have cardiac amyloidosis and are already planning to get this scan.
This trial uses a special brain scan (PET/CT) to look at a protein called alpha-synuclein in people with Parkinson's disease. The goal is to learn more about the disease and how it affects the brain.
This study uses special PET brain scans to look at proteins linked to Alzheimer's disease, which may help diagnose it and track how it changes over time.
This study uses brain scans to see how anti-amyloid treatments affect tau protein buildup in people with early Alzheimer's. If you have mild cognitive impairment or mild Alzheimer's, you may be eligible to help understand how these treatments work.
This study uses an amyloid PET/CT scan to see how well first-line treatment is working in people with AL cardiac amyloidosis, a condition where abnormal proteins build up in the heart. The scan may help doctors better understand and monitor the disease.
This trial studies how the brain removes amyloid-β, a protein linked to Alzheimer’s disease. It may help researchers understand what’s happening in people with mild memory impairment or Alzheimer’s, and guide better treatments in the future.
Hear when a new Amyloid trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.